NCT06555731|Completed
Ultra Rapid GEnome Sequencing
URGES
Long-read Human Genome Sequencing in 72 Hours: "Ultra Rapid GEnome Sequencing"
Loading search results
URGES
Long-read Human Genome Sequencing in 72 Hours: "Ultra Rapid GEnome Sequencing"
Sponsor study identifier
observational
4
1 country
1
Study Start
October 8, 2024
Actual (reported)Primary Completion
October 12, 2024
Actual (reported)Study Completion
October 12, 2024
Actual (reported)Next-generation sequencing (NGS) has revolutionized the field of genomics, allowing the detection of genetic abnormalities for diagnostic or therapeutic purposes. Turnaround times for exome or genome sequencing results have decreased to an average of 3 to 6 months. An increasing number of diagnostic and therapeutic fields are benefiting from the advancements in ultra-rapid sequencing. In some situations, a shorter turnaround time may be useful for making therapeutic and/or interventional management decisions. This study aims to explore the feasibility of very rapid whole-genome sequencing, ultra-rapid genome sequencing (URGES) in 72 hours, that could benefit patients with cancer or rare diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 12, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 13, 2024
Actual (reported)August 15, 2024
Actual (reported)October 8, 2024
Actual (reported)October 12, 2024
Actual (reported)October 12, 2024
Actual (reported)Time (in hours) for long read human genome sequencing and data interpretation
Time (in hours) to complete a long-read human genome sequencing, from the extracted DNA to the molecular and clinical results
72 hours
Sequencing coverage
72 hours
Sequencing depth
72 hours
Number of variants called appropriately or not
72 hours
DNA extraction from blood sample and whole genome sequencing
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adults with no known progressive or chronic diseases
Institut Rafaël
Levallois-Perret, Île-de-France Region, 92300, France
4 participants (actual enrollment reported by the registry).
First Submitted
August 13, 2024
First Posted
August 15, 2024
Study Start
October 8, 2024
Actual (reported)Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer
Contact the study team to confirm eligibility.
Primary Completion
October 12, 2024
Actual (reported)Study Completion
October 12, 2024
Actual (reported)Last Updated
December 18, 2024
Record last verified: 2024-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: